Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of S-Tocainide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A known ✓ | Q9NY46 | 2/20 | 0.45 |
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 0.45 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.45 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.45 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.45 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.51 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tocainide SCHEMBL15761 | 1.00 | ATM (0.57) | ATMHSP90AA1XIAPBIRC2TAAR1 | |
| Tocainide SCHEMBL9614374 | 0.98 | ATM (0.55) | ATMHSP90AA1XIAPBIRC2TAAR1 | |
| Tocainide SCHEMBL122779 | 0.98 | ATM (0.55) | ATMHSP90AA1XIAPBIRC2TAAR1 | |
| Tocainide SCHEMBL4338155 | 0.96 | ATM (0.54) | ATMHSP90AA1XIAPBIRC2TAAR1 | |
| Tocainide SCHEMBL27874301 | 0.95 | ATM (0.53) | ATMHSP90AA1XIAPBIRC2TAAR1 | |
| SCHEMBL11423763 | 0.87 | NLRP3 (0.52) | ATMANPEPALDH1A1MEN1KMT2A | |
| SCHEMBL11436632 | 0.85 | ATM (0.54) | ATMHSP90AA1ANPEPALDH1A1DRD2 | |
| SCHEMBL12832472 | 0.84 | ATM (0.60) | ATMHSP90AA1ANPEPALDH1A1DRD2 | |
| Tocainide SCHEMBL13724527 | 0.84 | SCN4A (0.65) | ATMHSP90AA1ANPEPHTR2AHTR2B | |
| SCHEMBL6356591 | 0.82 | ATM (0.58) | ATMHSP90AA1ANPEPALDH1A1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 510 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2009519467-A | — | — | 2009-05-14 | — | — | JP | claimed |
| EP-1990639-A1 | System and method for real-time diagnosis, treatment, and therapeutic drug monitoring | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-11-12 | — | — | EP | claimed |
| EP-1960775-A2 | SYSTEM AND METHOD FOR MONITORING HEALTH USING EXHALED BREATH | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-08-27 | — | — | EP | claimed |
| US-20070258894-A1 | System and Method for Real-Time Diagnosis, Treatment, and Therapeutic Drug Monitoring | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2007-11-08 | — | — | US | claimed |
| JP-2007525670-A | — | — | 2007-09-06 | — | — | JP | claimed |
| WO-2007089328-A2 | SYSTEM AND METHOD FOR MONITORING HEALTH USING EXHALED BREATH | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2007-08-09 | — | — | WO | claimed |
| US-20070167853-A1 | System and method for monitoring health using exhaled breath | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2007-07-19 | — | — | US | claimed |
| EP-1718971-A2 | SYSTEM AND METHOD FOR REAL-TIME DIAGNOSIS, TREATMENT, AND THERAPEUTIC DRUG MONITORING | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2006-11-08 | — | — | EP | claimed |
| WO-2005098429-A2 | SYSTEM AND METHOD FOR REAL-TIME DIAGNOSIS, TREATMENT, AND THERAPEUTIC DRUG MONITORING | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2005-10-20 | — | — | WO | claimed |
| US-20050233459-A1 | Marker detection method and apparatus to monitor drug compliance | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2005-10-20 | — | — | US | claimed |
| WO-2005056113-A1 | COMPOUNDS FOR THE TREATMENT OF OCULAR DRYNESS CAUSED BY PHOTOREFRACTIVE SURGERY | UNIVERSIDAD MIGUEL HERNANDEZ (ES) | 2005-06-23 | — | — | WO | claimed |
| US-20050054942-A1 | System and method for therapeutic drug monitoring | UNIVERSITY OF FLORIDA | 2005-03-10 | — | — | US | claimed |
| EP-1183011-A4 | METHOD OF TREATING ANGINA AND/OR ANGINAL EQUIVALENTS, AND PHARMACEUTICAL COMPOSITIONS AND KIT RELATED THERETO | ESPERION LUV DEV INC (US) | 2005-01-19 | — | — | EP | claimed |
| JP-2003508349-A | — | — | 2003-03-04 | — | — | JP | claimed |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-25 | — | — | US | claimed |
| EP-1183011-A1 | METHOD OF TREATING ANGINA AND/OR ANGINAL EQUIVALENTS, AND PHARMACEUTICAL COMPOSITIONS AND KIT RELATED THERETO | Esperion Mergerco, Inc. (US) | 2002-03-06 | — | — | EP | claimed |
| WO-2001092283-A2 | COBALAMIN COMPOUNDS USEFUL AS CARDIOVASCULAR AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |
| WO-2000069412-A1 | METHOD OF TREATING ANGINA AND/OR ANGINAL EQUIVALENTS, AND PHARMACEUTICAL COMPOSITIONS AND KIT RELATED THERETO | ESPERION LUV DEVELOPMENT, INC. (US) | 2000-11-23 | — | — | WO | claimed |
| US-12605384-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| WO-1996032100-A1 | COMPOSITIONS AND METHODS FOR TREATING PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | APOB, MMAB, CBS | SCN3A 3723/4885SCN4A 3757/4885SCN5A 3192/4885 |
| US-12605384-B2 | Uses | PDE2A, NPR1, PDE7A | SCN3A 474/4885SCN4A 1411/4885SCN5A 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.